Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: pegylated interferon alfa Clear all

Conditions: Hepatitis C
Interventions: Interferon-alpha; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Tucson, Arizona • Atlanta, Georgia

Conditions: Myelofibrosis
Interventions: Peginterferon alfa-2a; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Hepatitis C
Interventions: Interferon Alfacon-1 and Ribavirin; Drug
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections, Hepatitis C
Interventions: Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 42
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Hepatitis C
Interventions: BI 201335, PegIFN/RBV; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 20
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 16 more

Conditions: Chronic Hepatitis C
Interventions: valopicitabine, pegylated interferon; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Timeline: Started 2004
U.S. locations: 2
States / cities: Bradenton, Florida • San Antonio, Texas

Conditions: Hepatitis C, Hepatitis
Interventions: Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 67
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more

Conditions: Hepatitis C, Genotype 1
Interventions: Daclatasvir, Ribavirin, PEG-Interferon alfa 2a; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 23
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more

Conditions: Chronic Hepatitis b
Interventions: AB-729, Peg-IFNα-2a; Drug
Lead sponsor: Arbutus Biopharma Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Chandler, Arizona • Tucson, Arizona • San Diego, California + 3 more

Conditions: Polycythemia Vera, Essential Thrombocythemia
Interventions: RG7388, Pegasys; Drug
Lead sponsor: John Mascarenhas; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina

Conditions: Myeloproliferative Disorders
Interventions: IFN-alpha2a; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HCV
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 19 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Essential Thrombocythemia
Interventions: Bomedemstat, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, Ruxolitinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Glendale, Arizona • Glendale, California • Stanford, California + 12 more

Conditions: Hepatitis B
Interventions: Entecavir and peginterferon; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 3 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: San Francisco, California • Baltimore, Maryland • Minneapolis, Minnesota + 3 more

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Highly Active Antiretroviral Therapy (HAART); Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 46
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Immunosuppressant Regimen; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: peginterferon alfa-2b, decitabine, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Localized Osteosarcoma, Metastatic Osteosarcoma
Interventions: Cisplatin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate, Peginterferon Alfa-2b, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery; Drug · Biological · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 5 Years to 40 Years
Enrollment: 1,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 186
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more

Conditions: Hepatitis D
Interventions: Peginterferon Alpha-2a; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV, Hepatitis C, Infections
Interventions: Pegylated interferon alfa and ribavirin (PEG-IFN/RBV); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 4
States / cities: Lancaster, California • Los Angeles, California

Conditions: Lymphoma
Interventions: Pegylated interferon α-2b, Psoralens with ultraviolet light A, Narrowband-ultraviolet light B; Biological · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hepatitis, Chronic Active
Interventions: CPG10101, Control; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 14
States / cities: Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more

Conditions: HIV, HIV/AIDS, HIV-1 Infection
Interventions: Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074; Drug
Lead sponsor: Luis Montaner; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes

Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Pegasys® in Patients With Myeloproliferative Diseases

Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3

Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Pegylated Interferon to Treat Chronic Hepatitis D

Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)